FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.pharm-quality
Resource TypeComposition
IdComposition-composition-drug-pq-formulation.json
FHIR VersionR5

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: Composition

Resource Composition "composition-drug-pq-formulation"

Profile: Composition - Drug PQ

status: final

type: Product Note - Formulation Development ()

date: 2023-10-01

author: Organization/organization-drug-pq-ex1 "AAA Molybdenum Products, Inc."

title: 3.2.P.2.2.1 - Formulation Development


Source1

{
  "resourceType": "Composition",
  "id": "composition-drug-pq-formulation",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/uv/pharm-quality/StructureDefinition/Composition-drug-pq"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "final",
  "type": {
    "text": "Product Note - Formulation Development"
  },
  "subject": [
    {
      "reference": "MedicinalProductDefinition/medicinalproductdefinition-drug-product-pq-ex1"
    }
  ],
  "date": "2023-10-01",
  "author": [
    {
      "reference": "Organization/organization-drug-pq-ex1"
    }
  ],
  "title": "3.2.P.2.2.1 - Formulation Development",
  "section": [
    {
      "title": "3.2.P.2.2.1.1 - Formulation History",
      "text": {
        "status": "additional",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                <ul>\n                    <li>Drug product description including difference or similarity between the drug product and reference product, if applicable</li>\n                    <li>Propose route of administration (include any dilution or reconstitution necessary)</li>\n                                <li>Choice of manufacturing process, explain choice if alternative process could have been applicable (e.g. aseptic processing instead of terminal sterilization, direct compression instead of granulation). If different processes were used for different formulation highlight and explain differences, refer at 3.2.P.2.3. If no change in the process occurred refer to 3.3.P.3.3 and avoid duplication data.</li>\n                </ul>\n                <p>Table 1 - Formulation history for Stelbatolol</p>\n                <table>\n                    <tr>\n                                    <th>Formulation Identifier</th>\n                                    <th>Composition</th>\n                                    <th>Change</th>\n                                    <th>Development phase</th>\n                    </tr>\n                    <tr>\n                                    <td>1233545</td>\n                                    <td>Composition 1a</td>\n                                    <td>Changes made are listed here</td>\n                                    <td>Pre-clinical phase</td>\n                    </tr>\n                </table>\n                            \n            </div>"
      }
    },
    {
      "title": "3.2.P.2.2.1.2 - Formulation Development Studies",
      "text": {
        "status": "additional",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                <p>Summary of the formulation developmental studies conducted are provided in Table 2</p>\n                <p>Table 2 - Formulation Development Studies</p>\n                <table>\n                    <tr>\n                                    <th>Study</th>\n                                    <th>Formulation identifier </th>\n                                    <th>Objective</th>\n                                    <th>Quality attribute evaluated</th>\n                                    <th>Study design</th>\n                                    <th>Study result</th>\n                                </tr>\n                                <tr>\n                                    <td>Study Name</td>\n                                    <td>12234a</td>\n                                    <td>Short description of the study objective</td>\n                                    <td>CQA information</td>\n                                    <td>Short description of the design</td>\n                                    <td>Reference to the table showing study results</td>\n                    </tr>\n                </table>\n                            \n            </div>"
      }
    },
    {
      "title": "3.2.P.2.2.4 - Summary for Risk Assessment of Elemental Impurities in Drug Product",
      "text": {
        "status": "additional",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                <p>Summary of the risk assessment for product...</p>\n            </div>"
      }
    }
  ]
}